Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in larger doses for COVID-19
NCT04351347Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Jun 2020
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tanta University. Primary endpoint: Number of patients with improvement or died at 1 month. Started Jun 2020; status: recruiting.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04351347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351347.